01. Doctor Overview

Doctor Overview

A top cancer researcher who has shown a keen interest in developing and investigating new treatment options for malignant mesothelioma, Dr. Hedy Lee Kindler is the Director of the Mesothelioma Program at UChicago Medicine, as well as the Medical Director of Gastrointestinal Oncology. Dr. Kindler also serves as a professor of medicine.

As a researcher, Kindler largely focuses on the research of novel drugs, like Alimta and gemcitabine for the treatment of mesothelioma. Her interest in the disease peaked when her father died of mesothelioma in 2001. In particular, Kindler’s research has centered on angiogenesis inhibitors and epidermal growth factor receptor inhibitors.

Dr. Kindler is an associate editor of Lung Cancer and a reviewer for a number of other medical journals, as well as author and co-author of numerous studies, journal articles and book chapters. Her work has garnered much attention in a number of cancer-related professional journals, including the Annals of Oncology, the Journals of Thoracic Oncology, and several others. Because of her expertise, she has lectured about mesothelioma and other conditions at hundreds of scientific meetings and conferences nationally and internationally.

02. Fast Facts

Doctor Fast Facts

Main Specialty: Oncology

Other Interests & Specialties: Oncology, gastrointestinal cancer, hematologic oncology, thoracic cancer, pancreatic cancer, gastrointestinal stromal tumors and malignant mesothelioma.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification, America’s Top Doctors for Cancer, America’s Top Doctors for Cancer, Chicago Magazine: Top Doctors, CMS Stage 1 EHR, Super Doc Award, Selikoff Lifetime Achievement Award from the Asbestos Disease Awareness Organization, member of Science Advisory Board of the Mesothelioma Foundation, the NCI Pancreatic Cancer Task Force, International Mesothelioma Interest Group and the Alliance for Clinical Trials in Oncology

Education & Experience:

  • Medical Degree from University at Buffalo, School of Medicine and Biomedical Sciences
  • Internship at UCLA Health System
  • Residency at UCLA Health System
  • Fellowship at Memorial Sloan Kettering Cancer Center
03. Publications


04. Mesothelioma Clinical Trials

Mesothelioma Clinical Trials by Hedy Lee Kindler, M.D.

Dr. Kindler is associated with the following clinical trials:

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Conditions: Mesothelioma, Lung Neoplasms

Last Updated: April 27, 2020

Status: Active, not recruiting

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Conditions: Mesothelioma

Last Updated: September 17, 2018

Status: Completed

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Conditions: Mesothelioma, Lung Neoplasms

Last Updated: August 26, 2016

Status: Terminated

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Conditions: Mesothelioma, Lung Neoplasms

Last Updated: July 25, 2014

Status: Completed

SU5416 in Treating Patients With Malignant Mesothelioma

Conditions: Mesothelioma, Lung Neoplasms

Last Updated: May 31, 2013

Status: Completed

Photo of Dr. Hedy Lee Kindler

Get Help Contacting Dr. Hedy Lee Kindler

Where Should We Overnight Your Free Guide?

    Privacy policy: All information is secure and will never be released